Your browser is no longer supported. Please, upgrade your browser.
NBIX Neurocrine Biosciences, Inc. daily Stock Chart
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E293.73 EPS (ttm)0.33 Insider Own1.20% Shs Outstand91.43M Perf Week-7.07%
Market Cap8.86B Forward P/E17.99 EPS next Y5.39 Insider Trans-11.09% Shs Float87.53M Perf Month-5.13%
Income37.00M PEG- EPS next Q0.58 Inst Own99.40% Short Float4.86% Perf Quarter-14.28%
Sales788.10M P/S11.25 EPS this Y74.70% Inst Trans-1.60% Short Ratio4.75 Perf Half Y-0.32%
Book/sh6.91 P/B14.03 EPS next Y51.48% ROA3.30% Target Price122.39 Perf Year22.84%
Cash/sh7.33 P/C13.22 EPS next 5Y- ROE7.00% 52W Range71.85 - 119.65 Perf YTD-9.82%
Dividend- P/FCF64.50 EPS past 5Y19.90% ROI6.00% 52W High-18.99% Beta1.45
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin99.10% 52W Low34.91% ATR3.40
Employees700 Current Ratio1.50 Sales Q/Q85.60% Oper. Margin9.20% RSI (14)34.13 Volatility3.77% 3.18%
OptionableYes Debt/Eq0.64 EPS Q/Q85.20% Profit Margin4.70% Rel Volume1.18 Prev Close104.12
ShortableYes LT Debt/Eq0.00 EarningsFeb 04 AMC Payout0.00% Avg Volume895.69K Price96.93
Recom1.90 SMA20-6.11% SMA50-8.87% SMA2000.03% Volume1,054,433 Change-6.91%
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Nov-21-18Initiated Canaccord Genuity Buy $111
Sep-10-18Initiated Morgan Stanley Overweight $145
Aug-07-18Initiated Stifel Buy $137
Feb-22-18Reiterated Needham Buy $95 → $110
Nov-02-17Reiterated H.C. Wainwright Buy $130 → $139
May-10-17Reiterated H.C. Wainwright Buy $100 → $130
May-05-17Initiated BofA/Merrill Buy $70
Feb-19-20 12:08PM  Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club Investor's Business Daily
Feb-15-20 07:37AM  Edited Transcript of NBIX earnings conference call or presentation 4-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Feb-07-20 09:28AM  Earnings Miss: Neurocrine Biosciences, Inc. Missed EPS By 52% And Analysts Are Revising Their Forecasts Simply Wall St.
Feb-05-20 09:35AM  Can Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Improve Its Returns? Simply Wall St.
Feb-04-20 05:55PM  Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results PR Newswire
07:51AM  The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares Benzinga
Feb-03-20 05:00PM  Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors PR Newswire
08:33AM  The Zacks Analyst Blog Highlights: Waters, Neurocrine Biosciences, Spirit Airlines, NuStar Energy and The RMR Group Zacks
Feb-02-20 01:04PM  The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus Benzinga
Jan-31-20 09:15AM  Late Rally Lifts Stocks Despite Coronavirus Concerns Zacks
07:48AM  5 Top Stocks Set to Beat Earnings Estimates Next Week Zacks
07:16AM  Bet on Earnings Beat With 5 Top-Ranked Stocks Zacks
Jan-28-20 12:31PM  Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Jan-20-20 04:30PM  Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results PR Newswire
10:02AM  Zacks.com featured highlights include: Zumiez, Neurocrine Biosciences and Covanta Zacks
Jan-17-20 08:22AM  Look Beyond Earnings Growth, Tap the Beat With These 3 Stocks Zacks
Jan-13-20 08:30AM  Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update GlobeNewswire -8.37%
Jan-12-20 06:30PM  Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones PR Newswire
Jan-10-20 11:40AM  AMRX vs. NBIX: Which Stock Is the Better Value Option? Zacks
01:00AM  Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy PR Newswire
Jan-09-20 12:10PM  Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-06-20 04:01PM  Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020 PR Newswire
10:31AM  Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Fair? Simply Wall St.
Dec-25-19 03:12PM  How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-23-19 07:06PM  3 Breakout Stocks of the Last Decade to Consider for 2020 Zacks
01:01AM  S&P Rises for Fourth Straight Week Zacks
Dec-19-19 07:05AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-18-19 02:38PM  The Top 10 Stocks of the Past Decade Kiplinger
Dec-07-19 08:45AM  Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting GlobeNewswire
Dec-06-19 11:11AM  With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Is Interesting Simply Wall St.
Dec-03-19 07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 07:30AM  Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy GlobeNewswire
Nov-27-19 06:52AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Nov-26-19 11:54PM  Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Nov-12-19 04:01PM  Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia PR Newswire
Nov-10-19 12:50AM  Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-05-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Nov-04-19 07:15PM  Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Third Quarter 2019 Financial Results PR Newswire
01:38PM  Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment? Simply Wall St.
Nov-01-19 08:53AM  Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX) Zacks
Oct-28-19 10:32AM  Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:30AM  CTLT vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Oct-22-19 03:56PM  Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)? Insider Monkey
Oct-15-19 10:10AM  Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4 Zacks
Oct-14-19 04:59PM  Selling Tools to Miners: The Stocks That Can Profit on Biotech and Prosthetics GuruFocus.com
04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results PR Newswire
09:15AM  Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out? Zacks
Oct-10-19 09:30AM  CTLT or NBIX: Which Is the Better Value Stock Right Now? Zacks
Oct-04-19 06:00PM  Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress PR Newswire
Oct-01-19 04:01PM  Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress PR Newswire
Sep-30-19 04:01PM  Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer PR Newswire
Sep-27-19 11:26AM  Investors Who Bought Neurocrine Biosciences (NASDAQ:NBIX) Shares Five Years Ago Are Now Up 476% Simply Wall St.
Sep-18-19 09:31AM  Buy These 7 Small Drugmakers to Boost Your Portfolio's Health Zacks
Sep-17-19 04:11PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders® PR Newswire
Sep-11-19 04:01PM  Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors PR Newswire
Sep-05-19 09:40AM  HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now? Zacks
Sep-04-19 09:15AM  Lannett (LCI) Hits 52-Week High, Can the Run Continue? Zacks
Aug-28-19 04:01PM  Neurocrine Biosciences to Present at Upcoming Healthcare Conferences PR Newswire
Aug-26-19 09:06AM  Is Neurocrine Biosciences (NBIX) a Great Growth Stock? Zacks
Aug-20-19 03:54PM  Edited Transcript of NBIX earnings conference call or presentation 29-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
08:33AM  Should You Be Worried About Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) 3.7% Return On Equity? Simply Wall St.
01:03AM  Another 1% Rally Provides a Strong Start to the Week Zacks
Aug-14-19 09:53AM  Why Neurocrine (NBIX) Could Be Positioned for a Surge Zacks
Aug-13-19 09:36AM  Moving Average Crossover Alert: Neurocrine Biosciences Zacks
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
Aug-09-19 09:25AM  Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run? Zacks
08:24AM  Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil Zacks
08:06AM  Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat Zacks
Aug-08-19 09:16PM  Neurocrine Biosciences Inc (NBIX) CEO Kevin Charles Gorman Sold $7.6 million of Shares GuruFocus.com
Aug-07-19 11:20AM  Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates Zacks
Aug-05-19 08:30AM  AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women PR Newswire
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
10:20AM  Why Neurocrine (NBIX) Might be Well Poised for a Surge Zacks
Jul-30-19 12:25PM  Why Neurocrine Biosciences Stock Is Jumping Today Motley Fool +10.33%
07:50AM  Dow Jones Futures: Beyond Meat Leads 5 Key Movers; Apple Earnings Loom Investor's Business Daily
06:00AM  Neurocrine Biosciences Posts Sizzling Sales Growth in Q2 Motley Fool
05:23AM  Neurocrine Biosciences Inc (NBIX) Q2 2019 Earnings Call Transcript Motley Fool
Jul-29-19 05:25PM  Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates Zacks
04:01PM  Neurocrine Biosciences Reports Second Quarter 2019 Financial Results PR Newswire
Jul-26-19 08:31AM  Should You Buy Neurocrine (NBIX) Ahead of Earnings? Zacks
Jul-22-19 07:28PM  8 Health-Care Stocks for Your Portfolio Kiplinger
10:31AM  Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? Zacks
Jul-15-19 10:17AM  Does Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) CEO Pay Reflect Performance? Simply Wall St.
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
Jul-10-19 04:10PM  Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease PR Newswire
Jul-08-19 04:01PM  Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results PR Newswire
Jun-11-19 04:01PM  Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders PR Newswire
01:49PM  Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX) Insider Monkey
Jun-04-19 04:01PM  Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference PR Newswire
03:12AM  Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
May-31-19 11:51AM  Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Trading At A 30% Discount? Simply Wall St.
May-30-19 04:01PM  Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference PR Newswire +5.99%
May-29-19 09:15AM  Not Ready to Rally Zacks
May-21-19 08:00AM  AbbVie Launches ORILISSA (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
May-20-19 08:00AM  Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life PR Newswire
May-16-19 04:01PM  Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting PR Newswire
May-08-19 09:15AM  Trade Anxieties Return with a Vengeance Zacks
Neurocrine Biosciences, Inc. discovers and develops treatments for patients with neurological, endocrine, and psychiatric disorders. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of adults with tardive dyskinesia; and ORILISSA (elagolix) for the management of moderate to severe endometriosis pain in women in the United States. It also develops opicapone, a catechol-o-methyltransferase inhibitor, for the treatment of Parkinson's disease patients; crinecerfont for the treatment of congenital adrenal hyperplasia; and NBIb-1817, an investigational gene therapy for the treatment of Parkinson's disease. In addition, the company is developing NBI-921352, an inhibitor being developed to treat pediatric patients with SCN8A-DEE and other potential indications, including adult focal epilepsy; and ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for potential use in certain forms of generalized epilepsy. Neurocrine Biosciences, Inc. has collaboration agreements with AbbVie Inc.; Mitsubishi Tanabe Pharma Corporation; BIAL Portela & Ca, S.A.; Jnana Therapeutics Inc.; Voyager Therapeutics, Inc.; and Xenon Pharmaceuticals Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise59.6628,9691,728,14739,127Feb 11 07:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale104.5628,9693,029,08623,200Feb 11 07:21 PM
ROBERTS EIRYChief Medical OfficerFeb 07Sale103.311,623167,6757,452Feb 11 07:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 07Sale103.281,015104,82723,200Feb 11 07:21 PM
Lippoldt DarinChief Legal OfficerFeb 07Sale103.321,522157,24724,124Feb 11 07:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 07Sale103.311,218125,833111,682Feb 11 07:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 07Sale103.353,248335,696432,357Feb 11 07:14 PM
Gano KyleChief Business Development OffFeb 07Sale103.331,623167,71091,975Feb 11 07:13 PM
Cooke JulieChief Human Resources OfficerFeb 07Sale103.2691394,2764,643Feb 11 07:10 PM
Bozigian Haig P.Chief Development OfficerFeb 07Sale103.331,623167,702146,641Feb 11 07:09 PM
BENEVICH ERICChief Commercial OfficerFeb 07Sale103.322,030209,74720,087Feb 11 07:08 PM
ABERNETHY MATTChief Financial OfficerFeb 07Sale103.352,030209,8075,701Feb 11 07:06 PM
Gano KyleChief Business Development OffFeb 06Sale101.411,000101,41390,514Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 06Sale101.4480381,456110,587Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 06Sale101.521,490151,25822,287Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 06Sale101.471,198121,55622,755Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 06Sale101.564,343441,068429,436Feb 07 06:44 PM
Bozigian Haig P.Chief Development OfficerFeb 06Sale101.561,395141,670145,180Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 06Sale101.481,395141,56118,262Feb 07 06:35 PM
Gano KyleChief Business Development OffFeb 05Sale103.053,690380,26287,204Feb 07 06:54 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale103.151,618166,894109,320Feb 07 06:50 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale103.051,948200,73320,455Feb 07 06:47 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale102.981,750180,20721,133Feb 07 06:46 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale103.095,449561,726423,351Feb 07 06:44 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale103.1760562,4173,821Feb 07 06:38 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale103.022,046210,779143,292Feb 07 06:37 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale103.031,954201,31116,279Feb 07 06:35 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.112,632292,4455,991Jan 10 04:10 PM
ABERNETHY MATTChief Financial OfficerDec 02Sale116.331,645191,3603,876Dec 04 06:06 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Option Exercise35.995,000179,950113,408Nov 19 05:37 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 18Sale115.985,000579,900108,408Nov 19 05:37 PM
Lippoldt DarinChief Legal OfficerNov 08Option Exercise32.9910,000329,90026,728Nov 13 04:36 PM
LYONS GARY ADirectorNov 08Sale110.005,000550,000225,697Nov 13 04:41 PM
Lippoldt DarinChief Legal OfficerNov 08Sale110.0110,0001,100,05720,103Nov 13 04:36 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Option Exercise32.9910,188336,102118,596Nov 05 04:37 PM
LYONS GARY ADirectorNov 01Sale100.225,000501,104230,697Nov 05 04:38 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 01Sale100.3410,1881,022,298108,408Nov 05 04:37 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Option Exercise15.459,956153,82029,569Oct 16 04:20 PM
Lloyd-Smith MalcolmChief Regulatory OfficerOct 14Sale90.859,956904,48719,613Oct 16 04:20 PM
Cooke JulieChief Human Resources OfficerOct 02Sale88.5698787,4093,276Oct 04 06:15 PM
Lippoldt DarinChief Legal OfficerSep 03Option Exercise32.996,736222,22126,839Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerSep 03Sale100.006,736673,60020,103Sep 05 04:09 PM
Lippoldt DarinChief Legal OfficerAug 27Option Exercise32.991,60052,78421,561Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 27Sale100.001,600160,00019,961Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Option Exercise32.991,66454,89521,625Aug 27 07:52 PM
Lippoldt DarinChief Legal OfficerAug 23Sale100.091,664166,55519,961Aug 27 07:52 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 09Option Exercise32.993,03199,993420,628Aug 13 04:44 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Option Exercise8.6626,330228,018443,927Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 08Sale95.6426,3302,518,154417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Option Exercise8.662,75923,893420,356Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 07Sale95.122,759262,440417,597Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Option Exercise8.6650,911440,889468,508Aug 08 07:39 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 06Sale95.1550,9114,844,380417,597Aug 08 07:39 PM
Bozigian Haig P.Chief Development OfficerJul 30Option Exercise38.9144,3561,725,704167,576Jul 31 07:11 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Option Exercise32.9950,0001,649,500168,408Jul 31 07:12 PM
Lippoldt DarinChief Legal OfficerJul 30Option Exercise18.1515,831287,33335,792Jul 31 07:14 PM
LYONS GARY ADirectorJul 30Sale92.0710,000920,686235,697Jul 31 07:15 PM
Lippoldt DarinChief Legal OfficerJul 30Sale92.1315,8311,458,56919,961Jul 31 07:14 PM
Grigoriadis Dimitri E.Chief Research OfficerJul 30Sale92.9260,0005,575,438108,408Jul 31 07:12 PM
Bozigian Haig P.Chief Development OfficerJul 30Sale92.7744,3564,114,858141,976Jul 31 07:11 PM
Bozigian Haig P.Chief Development OfficerJul 15Option Exercise32.9930,6801,012,133172,656Jul 17 07:08 PM
Bozigian Haig P.Chief Development OfficerJul 15Sale87.5030,6802,684,506141,976Jul 17 07:08 PM
BENEVICH ERICChief Commercial OfficerJul 15Sale87.445,835510,20114,910Jul 17 07:06 PM
Bozigian Haig P.Chief Development OfficerJul 11Option Exercise32.991003,299142,076Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 11Sale87.591008,759141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Option Exercise32.997,120234,889149,096Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJul 10Sale87.637,120623,958141,976Jul 12 04:15 PM
Bozigian Haig P.Chief Development OfficerJun 18Option Exercise32.992,10069,279144,076Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 18Sale87.822,100184,417141,976Jun 20 05:56 PM
Bozigian Haig P.Chief Development OfficerJun 13Option Exercise20.7017,268357,469157,812Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 13Sale82.6217,2681,426,628141,976Jun 17 05:47 PM
Bozigian Haig P.Chief Development OfficerJun 03Option Exercise19.593,43567,292145,411Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerJun 03Sale85.513,435293,719141,976Jun 05 06:26 PM
Bozigian Haig P.Chief Development OfficerMay 31Option Exercise19.5919,297378,028161,273Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 31Sale85.0219,2971,640,581141,976Jun 03 06:18 PM
Bozigian Haig P.Chief Development OfficerMay 24Option Exercise19.5917,486342,551159,462May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 24Sale80.0317,4861,399,434141,976May 29 05:45 PM
Bozigian Haig P.Chief Development OfficerMay 22Option Exercise19.591,30025,467143,276May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 22Sale80.031,300104,037141,976May 23 06:27 PM
Bozigian Haig P.Chief Development OfficerMay 16Option Exercise17.5866,6671,171,789176,352May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 16Sale80.1366,6675,341,893141,976May 20 06:36 PM
Bozigian Haig P.Chief Development OfficerMay 13Option Exercise8.6634,547299,177176,523May 15 07:23 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 13Sale75.441,657125,007118,408May 15 07:24 PM
Bozigian Haig P.Chief Development OfficerMay 13Sale75.5134,5472,608,813141,976May 15 07:23 PM